TP53 and B-cell chronic lymphocytic leukemia: In chronic lymphocytic leukaemia (CLL), chemo-immunotherapy (CIT) with fludarabine, cyclophosphamide and rituximab (FCR) is now well established as a standard of care for young treatment-naive, fit patients without TP53 locus alterations (mutations and/or deletions) and with normal renal function [1, 2].